MGWM
GILD icon

Marks Group Wealth Management’s Gilead Sciences GILD Stock Holding History

Marks Group Wealth Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278K Buy
2,201
+201
+10% +$26.5K 0.02% 321
2026
Q1 		$279K Sell
2,000
-1,154
-37% -$162K 0.03% 301
2025
Q4 		$387K Buy
+3,154
New +$383K 0.04% 262

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marks Group Wealth Management's GILD Position: Q2 2026 in Review

Marks Group Wealth Management increased its Gilead Sciences (GILD) stake by 10% in Q2 2026, buying an estimated $26.5K and bringing the position to 2,201 shares worth $278K. The position accounts for 0.02% of the portfolio, ranked #321.

Marks Group Wealth Management first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. The position peaked at $387K in Q4 2025. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Marks Group Wealth Management held 2,201 shares of Gilead Sciences worth $278K as of Q2 2026.
  • Marks Group Wealth Management bought 201 Gilead Sciences shares in Q2 2026, an estimated $26.5K.
  • Gilead Sciences made up 0.02% of Marks Group Wealth Management's portfolio in Q2 2026, its #321 holding.
  • Marks Group Wealth Management first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • Marks Group Wealth Management's Gilead Sciences position peaked at $387K in Q4 2025.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Marks Group Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.